This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Auernhammer, C. J. Articles by Melmed, S. Search for Related Content PubMed PubMed Citation Articles by Auernhammer, C. J. Articles by Melmed, S.

Leukemia Inhibitory Factor Modulates Interleukin-1ß-Induced Activation of the Hypothalamo-Pituitary-Adrenal Axis¹

Division of Endocrinology and Metabolism, Cedars-Sinai Research Institute, University of California School of Medicine, Los Angeles, California 90048

Address all correspondence and requests for reprints to: Dr. Shlomo Melmed, Division of Endocrinology and Metabolism, Cedars-Sinai Medical Center, 8700 Beverly Boulevard, B-131, Los Angeles, California 90048. E-mail: melmed{at}cshs.org

We have shown that leukemia inhibitory factor (LIF) is expressed in corticotroph cells and stimulates POMC gene expression and ACTH secretion in vivo and in vitro. We therefore examined the regulation of in vitro and in vivo pituitary LIF expression by cytokines known to stimulate the hypothalamo-pituitary-adrenal axis. In the corticotroph cell line AtT-20/D16v-F2, recombinant murine interleukin-1ß (IL-1ß; 0.1–10.0 ng/ml) caused a 5- to 10-fold increase in LIF messenger RNA (mRNA) levels. LIF mRNA expression was induced as early as 1 h, peaked at 2 h, and still persistently elevated above the baseline after 8 h. This effect of IL-1ß on LIF mRNA expression was abolished by preincubation with human IL-1 receptor antagonist (100 ng/ml) or antimurine IL-1ß antibody (10 µg/ml). Tumor necrosis factor- (20 ng/ml) only modestly increased LIF mRNA, but was synergistic with IL-1ß (up to 2.5-fold). In contrast, IL-2 and IL-6 did not alter LIF mRNA. In C57BL/6 mice, ip injection of 100 ng IL-1ß increased plasma ACTH and corticosterone levels after 1 h (P < 0.02). In addition, pituitary LIF mRNA content was increased for up to 2 h in response to IL-1ß. In comparison to wild-type (+/+) B6D2F1 mice, LIF knockout mice with a deleted LIF gene (-/-) exhibited decreased plasma ACTH (631 ± 61 vs. 376 ± 50 pg/ml; P < 0.01) and corticosterone (783 ± 85 vs. 433 ± 51 ng/ml; P < 0.01) levels 1 h after ip IL-1ß administration. In conclusion, corticotroph LIF mRNA expression is specifically stimulated by IL-1ß and tumor necrosis factor-. The attenuated hypothalamo-pituitary-adrenal response to IL-1ß in LIF knockout mice indicates that the effect of IL-1ß on ACTH secretion is modulated by LIF. Thus, LIF appears to function as an immune-neuroendocrine modulator signaling the hypothalamo-pituitary-adrenal axis.

This article has been cited by other articles:

				D. Chida, T. Imaki, T. Suda, and Y. Iwakura Involvement of Corticotropin-Releasing Hormone- and Interleukin (IL)-6-Dependent Proopiomelanocortin Induction in the Anterior Pituitary during Hypothalamic-Pituitary-Adrenal Axis Activation by IL-1{alpha} Endocrinology, December 1, 2005; 146(12): 5496 - 5502. [Abstract] [Full Text] [PDF]

				A. Kariagina, D. Romanenko, S.-G. Ren, and V. Chesnokova Hypothalamic-Pituitary Cytokine Network Endocrinology, January 1, 2004; 145(1): 104 - 112. [Abstract] [Full Text] [PDF]

				J.-I. Park, C. J. Strock, D. W. Ball, and B. D. Nelkin The Ras/Raf/MEK/Extracellular Signal-Regulated Kinase Pathway Induces Autocrine-Paracrine Growth Inhibition via the Leukemia Inhibitory Factor/JAK/STAT Pathway Mol. Cell. Biol., January 15, 2003; 23(2): 543 - 554. [Abstract] [Full Text] [PDF]

				V. Chesnokova and S. Melmed Minireview: Neuro-Immuno-Endocrine Modulation of the Hypothalamic-Pituitary-Adrenal (HPA) Axis by gp130 Signaling Molecules Endocrinology, May 1, 2002; 143(5): 1571 - 1574. [Abstract] [Full Text] [PDF]

				J. Liu, C. Lin, A. Gleiberman, K. A. Ohgi, T. Herman, H.-P. Huang, M.-J. Tsai, and M. G. Rosenfeld Tbx19, a tissue-selective regulator of POMC gene expression PNAS, July 5, 2001; (2001) 141234898. [Abstract] [Full Text] [PDF]

				V. Chesnokova and S. Melmed Leukemia Inhibitory Factor Mediates the Hypothalamic Pituitary Adrenal Axis Response to Inflammation Endocrinology, November 1, 2000; 141(11): 4032 - 4040. [Abstract] [Full Text] [PDF]

				J. Schwartz Intercellular Communication in the Anterior Pituitary Endocr. Rev., October 1, 2000; 21(5): 488 - 513. [Abstract] [Full Text]

				A. Slominski, J. Wortsman, T. Luger, R. Paus, and S. Solomon Corticotropin Releasing Hormone and Proopiomelanocortin Involvement in the Cutaneous Response to Stress Physiol Rev, July 1, 2000; 80(3): 979 - 1020. [Abstract] [Full Text] [PDF]

				C. J. Auernhammer and S. Melmed Leukemia-Inhibitory Factor--Neuroimmune Modulator of Endocrine Function Endocr. Rev., June 1, 2000; 21(3): 313 - 345. [Abstract] [Full Text]

				S. G. Ren, J. Seliktar, X. Li, J. M. Hershman, G. D. Braunstein, and S. Melmed In Vivo and in Vitro Regulation of Thyroid Leukemia Inhibitory Factor (LIF): Marker of Hypothyroidism J. Clin. Endocrinol. Metab., August 1, 1999; 84(8): 2883 - 2887. [Abstract] [Full Text]

				C. J. Auernhammer, C. Bousquet, and S. Melmed Autoregulation of pituitary corticotroph SOCS-3 expression: Characterization of the murine SOCS-3 promoter PNAS, June 8, 1999; 96(12): 6964 - 6969. [Abstract] [Full Text] [PDF]

				C. J. Auernhammer and S. Melmed Interleukin-11 Stimulates Proopiomelanocortin Gene Expression and Adrenocorticotropin Secretion in Corticotroph Cells: Evidence for a Redundant Cytokine Network in the Hypothalamo-Pituitary-Adrenal Axis Endocrinology, April 1, 1999; 140(4): 1559 - 1566. [Abstract] [Full Text]

				E. A. Ratovitski, M. R. Alam, R. A. Quick, A. McMillan, C. Bao, C. Kozlovsky, T. A. Hand, R. C. Johnson, R. E. Mains, B. A. Eipper, et al. Kalirin Inhibition of Inducible Nitric-oxide Synthase J. Biol. Chem., January 8, 1999; 274(2): 993 - 999. [Abstract] [Full Text] [PDF]

				H. Yano, C. Readhead, M. Nakashima, S.-G. Ren, and S. Melmed Pituitary-Directed Leukemia Inhibitory Factor Transgene Causes Cushing's Syndrome: Neuro-Immune-Endocrine Modulation of Pituitary Development Mol. Endocrinol., November 1, 1998; 12(11): 1708 - 1720. [Abstract] [Full Text]

				C. J. Auernhammer, V. Chesnokova, C. Bousquet, and S. Melmed Pituitary Corticotroph SOCS-3: Novel Intracellular Regulation of Leukemia-Inhibitory Factor-Mediated Proopiomelanocortin Gene Expression and Adrenocorticotropin Secretion Mol. Endocrinol., July 1, 1998; 12(7): 954 - 961. [Abstract] [Full Text]

				S. Reichlin Editorial: What's In a Name or What Does Leukemia Inhibitory Factor Have to Do with the Pituitary Gland? Endocrinology, May 1, 1998; 139(5): 2199 - 2200. [Full Text] [PDF]

				V. Chesnokova, C. J. Auernhammer, and S. Melmed Murine Leukemia Inhibitory Factor Gene Disruption Attenuates the Hypothalamo-Pituitary-Adrenal Axis Stress Response Endocrinology, May 1, 1998; 139(5): 2209 - 2216. [Abstract] [Full Text] [PDF]

				J. Liu, C. Lin, A. Gleiberman, K. A. Ohgi, T. Herman, H.-P. Huang, M.-J. Tsai, and M. G. Rosenfeld Tbx19, a tissue-selective regulator of POMC gene expression PNAS, July 17, 2001; 98(15): 8674 - 8679. [Abstract] [Full Text] [PDF]

				V. Chesnokova, A. Kariagina, and S. Melmed Opposing effects of pituitary leukemia inhibitory factor and SOCS-3 on the ACTH axis response to inflammation Am J Physiol Endocrinol Metab, May 1, 2002; 282(5): E1110 - E1118. [Abstract] [Full Text] [PDF]